Key Points
- Vicki Sato sold 22,000 shares of Vir Biotechnology on Feb. 2 at an average price of $7.71 for about $169,620, trimming her holdings to 1,144,391 shares (a 1.89% reduction).
- Vir posted a sizable quarterly earnings miss (EPS $(1.17) vs. consensus $(0.70)) with just $0.24M in revenue, very negative margins and ROE, and analysts project full-year EPS of about -3.92.
- The stock trades near $7.68 with a market cap of roughly $1.07B; analyst coverage is mixed but averages a "Moderate Buy" rating with an average price target of $17.00.
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) Director Vicki Sato sold 22,000 shares of the business's stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $7.71, for a total value of $169,620.00. Following the completion of the sale, the director directly owned 1,144,391 shares of the company's stock, valued at $8,823,254.61. The trade was a 1.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Vir Biotechnology Stock Down 0.4%
NASDAQ VIR opened at $7.68 on Wednesday. Vir Biotechnology, Inc. has a 52 week low of $4.16 and a 52 week high of $10.67. The business has a 50 day moving average price of $6.46 and a 200-day moving average price of $5.74. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -2.13 and a beta of 1.69.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($1.17) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.47). Vir Biotechnology had a negative net margin of 2,963.54% and a negative return on equity of 50.76%. The business had revenue of $0.24 million for the quarter, compared to the consensus estimate of $1.98 million. During the same quarter last year, the firm posted ($1.56) EPS. The business's revenue for the quarter was up .8% compared to the same quarter last year. On average, equities research analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research firms have issued reports on VIR. HC Wainwright reiterated a "buy" rating and set a $15.00 price target on shares of Vir Biotechnology in a research note on Tuesday, December 30th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vir Biotechnology in a report on Monday, December 22nd. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $17.00.
Check Out Our Latest Research Report on VIR
Institutional Trading of Vir Biotechnology
A number of large investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. purchased a new position in Vir Biotechnology in the second quarter valued at about $35,000. FNY Investment Advisers LLC purchased a new position in Vir Biotechnology in the third quarter valued at approximately $38,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Vir Biotechnology by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company's stock valued at $41,000 after purchasing an additional 1,390 shares during the last quarter. Federated Hermes Inc. grew its holdings in Vir Biotechnology by 153.8% during the third quarter. Federated Hermes Inc. now owns 8,085 shares of the company's stock valued at $46,000 after purchasing an additional 4,899 shares during the period. Finally, Apollon Wealth Management LLC purchased a new stake in Vir Biotechnology in the second quarter worth $50,000. Hedge funds and other institutional investors own 65.32% of the company's stock.
Vir Biotechnology Company Profile
(
Get Free Report)
Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.
The company's pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
